IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Study sponsor: Immunocore Ltd
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-10-16Estimated
Enrollment · participants680Estimated
Source updated2026-02-25Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.